Advertisement
U.S. markets open in 6 hours 55 minutes
  • S&P Futures

    5,208.75
    -6.00 (-0.12%)
     
  • Dow Futures

    39,212.00
    -11.00 (-0.03%)
     
  • Nasdaq Futures

    18,187.00
    -44.50 (-0.24%)
     
  • Russell 2000 Futures

    2,048.30
    -1.50 (-0.07%)
     
  • Crude Oil

    82.57
    -0.15 (-0.18%)
     
  • Gold

    2,159.50
    -4.80 (-0.22%)
     
  • Silver

    25.12
    -0.14 (-0.55%)
     
  • EUR/USD

    1.0870
    -0.0007 (-0.07%)
     
  • 10-Yr Bond

    4.3400
    0.0000 (0.00%)
     
  • Vix

    14.33
    -0.08 (-0.56%)
     
  • GBP/USD

    1.2709
    -0.0019 (-0.15%)
     
  • USD/JPY

    150.3920
    +1.2940 (+0.87%)
     
  • Bitcoin USD

    64,958.14
    -3,450.11 (-5.04%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,722.55
    -4.87 (-0.06%)
     
  • Nikkei 225

    40,003.60
    +263.20 (+0.66%)
     

Digipath, Inc. to Hold Corporate Update Conference Call

LAS VEGAS, NV--(Marketwired - Dec 5, 2016) - Digipath, Inc. (OTCQB: DIGP), an independent cannabis lab testing and media firm, is pleased to announce that it will hold a corporate update conference call on Wednesday, December 7th, at 4:15pm ET. The purpose of the call is to provide an update on Digipath's organic growth strategy, acquisition strategy, developments in the Nevada market post recreational legalization and the Company's expanding technological capabilities.

On the call from Digipath will be Joe Bianco (CEO), Todd Denkin (COO/President) and Cindy Orser (Chief Science Officer). Each member of the management team will discuss:

Tood Denkin, Founder and President:

  • Digipath Labs in Las Vegas

  • Digipath's leadership position in the marketplace

  • On the ground business dynamics of the NV marketplace

  • The impact of recreational MJ passing in NV

Joe Bianco, CEO:

  • Capitalizing on Digipath's NV success

  • Plans for expansion and why it's such a good move NOW

  • Strategic licensing and joint venture opportunities

  • M&A opportunities for Digipath

Cindy Orser, PhD, Chief Science Officer:

  • How Nevada has set the standard for other MMJ states to follow

  • Why standardization in cannabis testing is needed

  • Integration of MMJ with retail MJ

  • Strain genotyping, chemometrics and the future

There will be a Q&A session towards the end of the conference call. Interested parties that want to submit questions must do so prior to the call by sending an email to hphillips@viridianca.com.

The dial-in numbers for the corporate update call are as follows:
Program Title: Digipath, Inc. Corporate Update
Call in US: 1-310-372-7549
Call in Canada: 1-647-478-7145
Conference Code: 348812

About Digipath, Inc.

Digipath, Inc. is an independent cannabis testing and media firm that supports the cannabis industry's best practices for reliable testing and delivers cannabis news coverage and education about the cannabis industry. Digipath's two business units are Digipath Labs and TNM News Corp. Digipath Labs™ is working to set the industry standard for testing all forms of cannabis-based products using FDA-compliant laboratory equipment and proprietary standard operating procedures (SOP) to ensure product safety and efficacy. TNM News Corp. has pioneered a cannabis-focused news network, The National Marijuana News, which delivers news, interviews, and education on all things cannabis. For more information please visit www.Digipath.com/

Forward-Looking Statements

This press release contains "forward-looking statements" that include information relating to future events, and future financial and operating performance. Forward looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: the Company's need for additional funding, governmental regulation of the cannabis industry, the demand for the Company's products, the introduction of new products, the Company's ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company's liquidity and financial strength to support its growth, and other information that may be detailed from time-to-time in the Company's filings with the United States Securities and Exchange Commission. For a more detailed description of the risk factors and uncertainties affecting Digipath, please refer to the Company's recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Advertisement